Clinical Trials Browser

Interventional × Ovarian Neoplasms × sacituzumab govitecan × Clear all

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Phase 1/2 Recruiting

Ovarian Neoplasms, Uterine Neoplasms